Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

The recurrence rates of Hepatocellular carcinoma (HCC) are high, necessitating novel and effective adjuvant therapies. Therefore, we conducted a phase II study of glypican-3 (GPC3) peptide vaccine as an adjuvant therapy for HCC patients. Forty-one patients with initial HCC who had undergone surgery...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Yu, Yoshikawa, Toshiaki, Ofuji, Kazuya, Yoshimura, Mayuko, Tsuchiya, Nobuhiro, Takahashi, Mari, Nobuoka, Daisuke, Gotohda, Naoto, Takahashi, Shinichiro, Kato, Yuichiro, Konishi, Masaru, Kinoshita, Taira, Ikeda, Masafumi, Nakachi, Kohei, Yamazaki, Naoya, Mizuno, Shoichi, Takayama, Tadatoshi, Yamao, Kenji, Uesaka, Katsuhiko, Furuse, Junji, Endo, Itaru, Nakatsura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910752/
https://www.ncbi.nlm.nih.gov/pubmed/27467945
http://dx.doi.org/10.1080/2162402X.2015.1129483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910752/
https://www.ncbi.nlm.nih.gov/pubmed/27467945
http://dx.doi.org/10.1080/2162402X.2015.1129483

Ejemplares similares